ARA-C, IDARUBICINE AND GENTUZUMAB OZOGAMICIN (AIM) AS SALVAGE TREATMENT IN ADVANCED ACUTE MYELOID LEUKEMIA PATIENTS

Main Article Content

saveria capria *
silvia maria trisolini
clara minotti
caterina stefanizzi
luisa cardarelli
Martina Canichella
claudio cartoni
daniela diverio
maria stefania de propris
marco mancini
alessandra micozzi
robin foà
giovanna meloni
(*) Corresponding Author:
saveria capria | capria@bce.uniroma1.it

Abstract

Long-term survival of relapsed/refractory acute myeloid leukemia (AML) remains a major problem, particularly in patients not eligible for transplantation.

We hereby evaluated the feasibility and efficacy of adding Gemtuzumab Ozogamicin to salvage chemotherapy (Ara-C, Idarubicine, Peg-Filgrastim) in relapsed/refractory AML. The main endpoints were: the rate of complete remissions (CR) and the proportion of patients capable of undergoing a stem cell transplant.

Fourty-two patients were enrolled. The overall CR rate was 76% and no induction deaths were reported. In 56% of patients, a transplant procedure could be performed. The treatment schedule proved feasible and well tolerated, providing a high CR rate and a useful bridge to transplant.


Downloads month by month

Downloads

Download data is not yet available.

Article Details

Author Biographies

saveria capria, Sapienza Università di Roma

Hematology, Department of Cellular Biotechnologies and Hematology

silvia maria trisolini, Sapienza Università di Roma

Hematology, Department of Cellular Biotechnologies and Hematology

clara minotti, Sapienza Università di Roma

Hematology, Department of Cellular Biotechnologies and Hematology

caterina stefanizzi, Sapienza Università di Roma

Hematology, Department of Cellular Biotechnologies and Hematology

luisa cardarelli, Sapienza Università di Roma

Hematology, Department of Cellular Biotechnologies and Hematology

claudio cartoni, Sapienza Università di Roma

Hematology, Department of Cellular Biotechnologies and Hematology

daniela diverio, Sapienza Università di Roma

Hematology, Department of Cellular Biotechnologies and Hematology

maria stefania de propris, Sapienza Università di Roma

Hematology, Department of Cellular Biotechnologies and Hematology

marco mancini, Sapienza Università di Roma

Hematology, Department of Cellular Biotechnologies and Hematology

alessandra micozzi, Sapienza Università di Roma

Hematology, Department of Cellular Biotechnologies and Hematology

robin foà, Sapienza Università di Roma

Hematology, Department of Cellular Biotechnologies and Hematology

giovanna meloni, Sapienza Università di Roma

Hematology, Department of Cellular Biotechnologies and Hematology

Most read articles by the same author(s)